Patent
Cas variants for gene editing
David R. Liu,Alexis C. Komor +1 more
Reads0
Chats0
TLDR
In this paper, the authors present strategies, systems, reagents, methods and kits for targeted nucleic acid editing, including editing a single site within the genome of a cell or subject, eg, within the human genome.Abstract:
To provide strategies, systems, reagents, methods and kits that are useful for targeted editing of nucleic acids, including editing a single site within the genome of a cell or subject, eg, within the human genomeSOLUTION: In some embodiments, fusion proteins of Cas9 and nucleic acid editing enzymes or nucleic acid editing enzyme domains, eg, deaminase domains, are provided In some embodiments, methods for targeted nucleic acid editing are provided In some embodiments, reagents and kits for generation of targeted nucleic acid editing proteins, eg, fusion proteins of Cas9 and nucleic acid editing enzymes or nucleic acid editing domains, are providedSELECTED DRAWING: Figure 3read more
Citations
More filters
Patent
Novel crispr enzymes and systems
TL;DR: In this article, the authors proposed a method for non-naturally occurring or engineered DNA or RNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA.
Patent
CRISPR-related methods and compositions with governing gRNAs
Alexandra Glucksmann,Deborah Palestrant,Louis Anthony Tartaglia,Jordi Mata-Fink,Agnieszka Czechowicz,Borisy Alexis +5 more
TL;DR: In this article, methods and compositions useful in targeting a payload to, or editing a target nucleic acid, where a governing gRNA molecule is used to target, optionally inactivate, a Cas9 molecule or a Cas 9 molecule/gRNA complex.
Patent
Delivery system for functional nucleases
TL;DR: In this paper, the authors present methods, methods, strategies, kits, and systems for the supercharged protein- mediated delivery of functional effector proteins into cells in vivo, ex vivo, or in vitro.
Patent
Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)
TL;DR: In this article, a CRISPR/CAS-related compositions and methods for treatment of Leber's Congenital Amaurosis 10 (LCAIO) are disclosed.
References
More filters
Journal ArticleDOI
A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.
Martin Jinek,Krzysztof Chylinski,Krzysztof Chylinski,Ines Fonfara,Michael H. Hauer,Jennifer A. Doudna,Emmanuelle Charpentier +6 more
TL;DR: This study reveals a family of endonucleases that use dual-RNAs for site-specific DNA cleavage and highlights the potential to exploit the system for RNA-programmable genome editing.
Journal ArticleDOI
Multiplex Genome Engineering Using CRISPR/Cas Systems
Le Cong,Le Cong,F. Ann Ran,F. Ann Ran,David M. Cox,David M. Cox,Shuailiang Lin,Shuailiang Lin,Robert P. J. Barretto,Naomi Habib,Patrick D. Hsu,Patrick D. Hsu,Xuebing Wu,Wenyan Jiang,Luciano A. Marraffini,Feng Zhang +15 more
TL;DR: The type II prokaryotic CRISPR (clustered regularly interspaced short palindromic repeats)/Cas adaptive immune system has been shown to facilitate RNA-guided site-specific DNA cleavage as discussed by the authors.
Journal ArticleDOI
Genome engineering using the CRISPR-Cas9 system
F. Ann Ran,Patrick D. Hsu,Jason Wright,Vineeta Agarwala,Vineeta Agarwala,David A. Scott,Feng Zhang +6 more
TL;DR: A set of tools for Cas9-mediated genome editing via nonhomologous end joining (NHEJ) or homology-directed repair (HDR) in mammalian cells, as well as generation of modified cell lines for downstream functional studies are described.
Journal ArticleDOI
RNA-Guided Human Genome Engineering via Cas9
Prashant Mali,Luhan Yang,Kevin M. Esvelt,John Aach,Marc Güell,James E. DiCarlo,Julie E. Norville,George M. Church,George M. Church +8 more
TL;DR: The type II bacterial CRISPR system is engineer to function with custom guide RNA (gRNA) in human cells to establish an RNA-guided editing tool for facile, robust, and multiplexable human genome engineering.
Journal ArticleDOI
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov,Serena Nik-Zainal,Serena Nik-Zainal,David C. Wedge,Samuel Aparicio,Sam Behjati,Sam Behjati,Andrew V. Biankin,Graham R. Bignell,Niccolo Bolli,Niccolo Bolli,Åke Borg,Anne Lise Børresen-Dale,Anne Lise Børresen-Dale,Sandrine Boyault,Birgit Burkhardt,Adam Butler,Carlos Caldas,Helen Davies,Christine Desmedt,Roland Eils,Jorunn E. Eyfjord,John A. Foekens,Mel Greaves,Fumie Hosoda,Barbara Hutter,Tomislav Ilicic,Sandrine Imbeaud,Sandrine Imbeaud,Marcin Imielinsk,Natalie Jäger,David T. W. Jones,David T. Jones,Stian Knappskog,Stian Knappskog,Marcel Kool,Sunil R. Lakhani,Carlos López-Otín,Sancha Martin,Nikhil C. Munshi,Nikhil C. Munshi,Hiromi Nakamura,Paul A. Northcott,Marina Pajic,Elli Papaemmanuil,Angelo Paradiso,John V. Pearson,Xose S. Puente,Keiran Raine,Manasa Ramakrishna,Andrea L. Richardson,Andrea L. Richardson,Julia Richter,Philip Rosenstiel,Matthias Schlesner,Ton N. Schumacher,Paul N. Span,Jon W. Teague,Yasushi Totoki,Andrew Tutt,Rafael Valdés-Mas,Marit M. van Buuren,Laura van ’t Veer,Anne Vincent-Salomon,Nicola Waddell,Lucy R. Yates,Icgc PedBrain,Jessica Zucman-Rossi,Jessica Zucman-Rossi,P. Andrew Futreal,Ultan McDermott,Peter Lichter,Matthew Meyerson,Matthew Meyerson,Sean M. Grimmond,Reiner Siebert,Elias Campo,Tatsuhiro Shibata,Stefan M. Pfister,Stefan M. Pfister,Peter J. Campbell,Peter J. Campbell,Peter J. Campbell,Michael R. Stratton,Michael R. Stratton +84 more
TL;DR: It is shown that hypermutation localized to small genomic regions, ‘kataegis’, is found in many cancer types, and this results reveal the diversity of mutational processes underlying the development of cancer.